Advisor Partners’s Takeda Pharmaceutical TAK Stock Holding History

Advisor Partners’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$395K	Sell	28,129 -206	-0.7%	-$2.94K	0.03%	554
2022 Q1	$406K	Buy	28,335 +12,608	+80%	+$185K	0.03%	578
2021 Q4	$215K	Sell	15,727 -11,360	-42%	-$159K	0.01%	798
2021 Q3	$444K	Buy	27,087 +761	+3%	+$12.8K	0.03%	517
2021 Q2	$443K	Buy	26,326 +211	+0.8%	+$3.59K	0.03%	542
2021 Q1	$477K	Buy	26,115 +2,589	+11%	+$46.6K	0.03%	492
2020 Q4	$428K	Sell	23,526 -7,879	-25%	-$138K	0.03%	494
2020 Q3	$560K	Buy	31,405 +7,708	+33%	+$140K	0.05%	355
2020 Q2	$425K	Buy	23,697 +9,678	+69%	+$174K	0.04%	406
2020 Q1	$212K	Buy	14,019 +1,224	+10%	+$22.2K	0.03%	534
2019 Q4	$256K	Buy	+12,795	New	+$245K	0.03%	538
2019 Q2	–	Sell	-11,214	Closed	-$228K	–	670
2019 Q1	$228K	Buy	+11,214	New	+$226K	0.03%	548

Other funds holding TAK

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Advisor Partners's TAK Position: Q2 2022 in Review

Advisor Partners reduced its Takeda Pharmaceutical (TAK) stake by 0.73% in Q2 2022, selling an estimated $2.94K and leaving 28,129 shares worth $395K. The position accounts for 0.03% of the portfolio, ranked #554.

Advisor Partners first reported a position in TAK in Q1 2019 and has held it in 12 quarters since. The position peaked at $560K in Q3 2020. 283 funds tracked by Wall St. Rank hold TAK as of Q2 2022.

Advisor Partners held 28,129 shares of Takeda Pharmaceutical worth $395K as of Q2 2022.
Advisor Partners sold 206 Takeda Pharmaceutical shares in Q2 2022, an estimated $2.94K.
Takeda Pharmaceutical made up 0.03% of Advisor Partners's portfolio in Q2 2022, its #554 holding.
Advisor Partners first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 12 quarters since.
Advisor Partners's Takeda Pharmaceutical position peaked at $560K in Q3 2020.
283 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2022.

Based on Advisor Partners's 13F filing for Q2 2022, filed 11 Aug 2022.